Veracyte, Inc.
As of Oct 22, 2026, Veracyte is in Stage 3, the topping phase, now in week 9 (since Aug 25, 2026). It closed at $46.04, 23.9% below its 52-week high and above its 200-day average, which is rising.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is VCYT early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
VCYT among Diagnostics & Research16th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …16 | VCYT | Stage 3 · wk 9 | 75 | +5.1% |
Veracyte: quick answers
What stage is Veracyte in?
As of Oct 22, 2026, Veracyte (VCYT) is in Stage 3, the topping phase. It entered Stage 3 on Aug 25, 2026 and is in week 9. What the four stages mean
Is Veracyte in an uptrend?
Its uptrend has stalled. Veracyte is in Stage 3, the topping phase that follows an advance. It trades 8.0% above its 200-day average, which is rising.
How far is Veracyte from its 52-week high?
Veracyte closed at $46.04 on Oct 22, 2026, 23.9% below its 52-week high of $60.49. Its 52-week low is $30.01.
How has Veracyte performed over the past year?
As of Oct 22, 2026, Veracyte is up 27.5% over the past year and up 8.6% so far in 2026.
Which sector and industry is Veracyte in?
Veracyte is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.